Beyond Spring Inc. BYSI
We take great care to ensure that the data presented and summarized in this overview for BeyondSpring Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BYSI
View all-
Decheng Capital LLC Menlo Park, CA4.53MShares$7.88 Million2.69% of portfolio
-
Vanguard Group Inc Valley Forge, PA524KShares$911,2360.0% of portfolio
-
Geode Capital Management, LLC Boston, MA256KShares$445,8080.0% of portfolio
-
Black Rock Inc. New York, NY215KShares$374,7170.0% of portfolio
-
Tanaka Capital Management Inc New York, NY26.3KShares$45,7550.09% of portfolio
-
Northern Trust Corp Chicago, IL16.3KShares$28,3770.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny11.6KShares$20,1840.0% of portfolio
-
Morgan Stanley New York, NY8.21KShares$14,2850.0% of portfolio
-
Bank Of America Corp Charlotte, NC7.77KShares$13,5210.0% of portfolio
-
Ubs Group Ag6.95KShares$12,0940.0% of portfolio
Latest Institutional Activity in BYSI
Top Purchases
Top Sells
About BYSI
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Insider Transactions at BYSI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 17
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
45,513
-2.91%
|
$45,513
$1.76 P/Share
|
|
Oct 16
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
85,798
-5.2%
|
$85,798
$1.72 P/Share
|
|
Oct 15
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
17,960
-1.08%
|
$17,960
$1.65 P/Share
|
|
Oct 14
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
28,495
-1.68%
|
$28,495
$1.65 P/Share
|
|
Oct 13
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
107,361
-5.95%
|
$107,361
$1.7 P/Share
|
|
Oct 10
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
2,390
-0.13%
|
$2,390
$1.77 P/Share
|
|
Oct 09
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
3,979
-0.22%
|
$3,979
$1.81 P/Share
|
|
Oct 08
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
7,507
-0.41%
|
$7,507
$1.77 P/Share
|
|
Oct 07
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
2,100
-0.12%
|
$2,100
$1.79 P/Share
|
|
Oct 06
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
17,500
-0.95%
|
$17,500
$1.78 P/Share
|
|
Oct 03
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
600
-0.03%
|
$600
$1.76 P/Share
|
|
Oct 02
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
600
-0.03%
|
$600
$1.73 P/Share
|
|
Oct 01
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
2,601
-0.14%
|
$2,601
$1.8 P/Share
|
|
Sep 30
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
4,464
-0.24%
|
$4,464
$1.81 P/Share
|
|
Sep 29
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
500
-0.03%
|
$500
$1.75 P/Share
|
|
Sep 26
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
600
-0.03%
|
$600
$1.68 P/Share
|
|
Sep 25
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
700
-0.04%
|
$700
$1.66 P/Share
|
|
Sep 24
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
2,256
-0.12%
|
$2,256
$1.68 P/Share
|
|
Sep 23
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
4,106
-0.22%
|
$4,106
$1.72 P/Share
|
|
Sep 22
2025
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. |
SELL
Open market or private sale
|
Indirect |
5,410
-0.29%
|
$5,410
$1.83 P/Share
|
Last 12 Months Summary
| Open market or private sale | 855K shares |
|---|